DE602006018334D1 - Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten - Google Patents

Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Info

Publication number
DE602006018334D1
DE602006018334D1 DE602006018334T DE602006018334T DE602006018334D1 DE 602006018334 D1 DE602006018334 D1 DE 602006018334D1 DE 602006018334 T DE602006018334 T DE 602006018334T DE 602006018334 T DE602006018334 T DE 602006018334T DE 602006018334 D1 DE602006018334 D1 DE 602006018334D1
Authority
DE
Germany
Prior art keywords
ylcarbonylazaspiroderivates
indol
receptor antagonists
vasopressin receptor
vasopressin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018334T
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602006018334D1 publication Critical patent/DE602006018334D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
DE602006018334T 2005-09-28 2006-09-18 Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten Active DE602006018334D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108966 2005-09-28
PCT/EP2006/066441 WO2007039438A1 (en) 2005-09-28 2006-09-18 Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists

Publications (1)

Publication Number Publication Date
DE602006018334D1 true DE602006018334D1 (de) 2010-12-30

Family

ID=37156049

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018334T Active DE602006018334D1 (de) 2005-09-28 2006-09-18 Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Country Status (17)

Country Link
US (1) US7790752B2 (de)
EP (1) EP1931680B1 (de)
JP (1) JP4908513B2 (de)
KR (1) KR101018934B1 (de)
CN (1) CN101273046B (de)
AR (1) AR057136A1 (de)
AT (1) ATE488519T1 (de)
AU (1) AU2006298828B2 (de)
BR (1) BRPI0616618A2 (de)
CA (1) CA2623715A1 (de)
DE (1) DE602006018334D1 (de)
ES (1) ES2354909T3 (de)
IL (1) IL189981A (de)
RU (1) RU2418801C2 (de)
TW (1) TWI327571B (de)
WO (1) WO2007039438A1 (de)
ZA (1) ZA200802339B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
US7799923B2 (en) * 2006-12-08 2010-09-21 Hoffmann-La Roche Inc. Indoles
CN101838269B (zh) * 2009-03-18 2012-09-26 中国人民解放军军事医学科学院毒物药物研究所 1,3,8-三氮杂-螺[4.5]癸烷-4-酮类化合物及其医药用途
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
EP3317279B1 (de) 2015-07-03 2021-01-27 H. Hoffnabb-La Roche Ag Triaza-spirodecanone als ddr1-inhibitoren
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769578B2 (ja) * 1989-10-13 1998-06-25 大塚製薬株式会社 バソプレシン拮抗剤
WO1998028292A1 (en) * 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
RS20050208A (en) * 2002-09-09 2007-08-03 Janssen Pharmaceutica N.V., Hydroxy alkyl substituted 1,3,8- triazaspiro/4,5/decan-4- one derivatives useful for the treatment of orl-1 receptor mediated disorders
EP1628978A2 (de) * 2003-05-23 2006-03-01 Zealand Pharma A/S Triaza-spiro-verbindungen als nociceptin-analoga und deren verwendung
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
ATE421511T1 (de) * 2005-07-14 2009-02-15 Hoffmann La Roche Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
ES2343286T3 (es) * 2006-12-07 2010-07-27 F. Hoffmann-La Roche Ag Derivados de espiro-piperidina.

Also Published As

Publication number Publication date
US7790752B2 (en) 2010-09-07
RU2008110409A (ru) 2009-11-10
KR101018934B1 (ko) 2011-03-02
BRPI0616618A2 (pt) 2011-06-28
KR20080049780A (ko) 2008-06-04
AU2006298828A1 (en) 2007-04-12
RU2418801C2 (ru) 2011-05-20
WO2007039438A1 (en) 2007-04-12
AU2006298828B2 (en) 2011-12-01
IL189981A (en) 2012-09-24
AR057136A1 (es) 2007-11-21
CN101273046A (zh) 2008-09-24
JP4908513B2 (ja) 2012-04-04
US20070072888A1 (en) 2007-03-29
ES2354909T3 (es) 2011-03-21
ATE488519T1 (de) 2010-12-15
CN101273046B (zh) 2011-05-25
TW200804392A (en) 2008-01-16
EP1931680B1 (de) 2010-11-17
JP2009510010A (ja) 2009-03-12
ZA200802339B (en) 2009-10-28
TWI327571B (en) 2010-07-21
CA2623715A1 (en) 2007-04-12
EP1931680A1 (de) 2008-06-18
IL189981A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
DK1740177T3 (da) Antagonister til muskarinfølsomme acetylcholinreceptorer
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE545633T1 (de) Als vasopressinantagonisten geeignete benzazepinderivate
ATE395335T1 (de) Als muscarinrezeptorantagonisten geeignete biphenylverbindungen
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
DK2009992T3 (da) Il-8 receptor-antagonister
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
ATE509944T1 (de) Peptidische vasopressin-rezeptoragonisten
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
ATE534628T1 (de) Urotensin ii-rezeptorantagonisten